Zalgen Labs


Zalgen Labs is dedicated to developing solutions for emerging viral threats, especially in neglected regions of the world. They focus on high-impact, neglected infectious diseases such as Ebola and Lassa virus, and have expanded to include SARS-CoV-2 testing. Their mission is to create and deploy medical countermeasures, including diagnostics, vaccines, and immunotherapeutics, to address unmet medical needs globally. They have built a team of skilled scientists and have achieved significant milestones including developing rapid diagnostic tests, securing funding, and establishing state-of-the-art facilities.

Industries

Health Diagnostics
Health Care
Biotechnology
Life Science
Therapeutics
Biotechnology Research

Nr. of Employees

small (1-50)

Zalgen Labs

7495 New Horizon Way, Suite 120, Frederick, MD 21703 USA


Patents

Arena virus monoclonal antibodies and uses

US-12358971-B2

View Details

Arenavirus monoclonal antibodies and uses

US-11198723-B2

View Details

Products

ReSARS CoV-2 (N) IgG ELISA Kit — RUO

Research-use ELISA for detection of IgG antibodies against SARS-CoV-2 nucleocapsid protein.

ReSARS CoV-2 (S-RBD) IgG ELISA Kit — RUO

Research-use ELISA for detection of IgG antibodies against the SARS-CoV-2 receptor-binding domain (S-RBD).

ReEBOV Antigen ELISA Kit — RUO

Research-use ELISA for detection of Ebola virus antigen.

ReEBOV Antigen Rapid Test — RUO (lateral flow)

Research-use lateral flow rapid antigen test for Ebola virus with point-of-care readout.

ReLASV Combo NP/PF GP IgG ELISA Kit — RUO

Research-use ELISA combining nucleoprotein and prefusion glycoprotein antigens for Lassa virus IgG detection.

Lassa glycoprotein antigen panels (recombinant lineage-specific constructs)

Catalog of recombinant Lassa virus glycoprotein antigens representing multiple viral lineages, available in linked and prefusion constructs.

View All Products

Services

Provision and sale of ELISA kits, lateral-flow rapid tests, recombinant antigens and monoclonal antibodies for research, investigational and clinical study use as labeled.

Custom expression and supply of recombinant viral glycoproteins, nucleoproteins, prefusion constructs and monoclonal antibodies for research and assay development.

Design and execution of field evaluations comparing rapid antigen tests and other assays to molecular reference methods during outbreak conditions.

Preparation and management of license and material transfer agreements (LMTAs) governing the transfer and permitted uses of controlled biological materials and reagents.

Supply of test kits and reagents to support clinical trials and epidemiological studies, including multi-year supply contracts for large-scale studies.

Expertise Areas

  • Diagnostics development and commercialization
  • Vaccine and immunotherapeutic R&D
  • Recombinant antigen and antibody reagent production
  • Field evaluation and outbreak diagnostics
  • Show More (4)

Key Technologies

  • ELISA
  • Lateral flow immunoassay (rapid diagnostic test)
  • Recombinant protein expression and purification
  • Monoclonal antibody generation
  • Show More (4)

News & Updates

Zalgen moves its headquarters to the life sciences epicenter in Frederick, Maryland.

Zalgen received a three-year contract from CEPI to provide test kits for the largest Lassa fever study in West Africa.

Zalgen licenses proprietary glycoprotein technology from Scripps to develop better diagnostic tests.

A study in PNAS reports that Zalgen's immunotherapeutic confers complete protection against advanced Lassa infections in non-human primates.

An article by Roberts, L. (Feb 2024) in Science discusses the importance of increased awareness of Lassa virus infections.

An article in PNAS reports data from a study at the University of Texas Medical Branch showing complete protection in primates.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.